MHC class II invariant chain–adjuvanted viral vectored vaccines enhances T cell responses in humans-Reference-Cited by-同舟云学术

MHC class II invariant chain–adjuvanted viral vectored vaccines enhances T cell responses in humans

Published:2020-06-17 Issue:548 Volume:12 Page:
ISSN:1946-6234
Container-title:Science Translational Medicine
language:en
Short-container-title:Sci. Transl. Med.

Author:

Esposito Ilaria¹^ORCID,Cicconi Paola²^ORCID,D’Alise Anna Morena³^ORCID,Brown Anthony¹^ORCID,Esposito Marialuisa³,Swadling Leo¹^ORCID,Holst Peter Johannes⁴⁵⁶^ORCID,Bassi Maria Rosaria⁴^ORCID,Stornaiuolo Mariano⁷^ORCID,Mori Federica³,Vassilev Ventzislav⁸,Li Wenqin¹,Donnison Timothy¹^ORCID,Gentile Chiara⁹,Turner Bethany¹,von Delft Annette¹^ORCID,Del Sorbo Mariarosaria³,Barra Federica³^ORCID,Contino Alessandra Maria³^ORCID,Abbate Adele³,Novellino Ettore⁷^ORCID,Thomsen Allan Randrup⁵^ORCID,Christensen Jan Pravsgaard⁵^ORCID,Lahm Armin³,Grazioli Fabiana³,Ammendola Virginia³,Siani Loredana³,Colloca Stefano³,Klenerman Paul¹²^ORCID,Nicosia Alfredo⁹¹⁰¹¹,Dorrell Lucy¹¹²,Folgori Antonella³^ORCID,Capone Stefania³^ORCID,Barnes Eleanor¹²^ORCID,Bliss Carly,Ghaffari Emma,Hartnell Felicity,Kopycinski Jakub,Makvandi-Nejad Shokouh,Nevin Verity,Borys Dorota,Boutriau Dominique,Cochard Landry,Lin Lan,Struyf Frank,Hanke Tomáš,Bannan Ciaran,Bergin Colim,Hoffman Matthias,Schmid Patrick,Vernazza Pietro,Gardiner Clair,Woods Elena,

Affiliation:

1. Nuffield Department of Medicine, University of Oxford, Oxford OX3 7BN, UK.

2. The Jenner Institute Laboratories, Nuffield Department of Medicine, University of Oxford, Oxford OX3 7DQ, UK.

3. ReiThera s.r.l., 00128 Rome, Italy.

4. Center for Medical Parasitology, University of Copenhagen, DK-2200 Copenhagen, Denmark.

5. Department of Immunology and Microbiology, University of Copenhagen, DK-2200 Copenhagen, Denmark.

6. InProTher ApS, BioInnovation Institute, 2200 Copenhagen, Denmark.

7. Department of Pharmacy, University of Naples Federico II, 80131 Naples, Italy.

8. GSK Vaccines, 1330 Rixensart, Belgium.

9. Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, 80131 Naples, Italy.

10. CEINGE-Biotecnologie Avanzate, via Gaetano Salvatore 486, 80145 Naples, Italy.

11. Keires AG, 4051 Basel, Switzerland.

12. Oxford NIHR Biomedical Research Centre, Headington OX3 9DU, UK.

Abstract

Administration of an MHC class II invariant chain–adjuvanted HCV vaccine in humans leads to enhanced immunogenicity via the proteasome pathway.

Funder

Medical Research Council

European Union Seventh Framework Programme under grant agreement for PEACHI

NIH USA

UK National Institute for Health Research

Wellcome Trust

Medical Research Council case studentship

Publisher

American Association for the Advancement of Science (AAAS)

Subject

General Medicine

Reference46 articles.

1. The multifaceted roles of the invariant chain CD74 — More than just a chaperone

2. MHC Class II-Associated Invariant Chain Linkage of Antigen Dramatically Improves Cell-Mediated Immunity Induced by Adenovirus Vaccines

3. Enhanced and Sustained CD8+T Cell Responses with an Adenoviral Vector-Based Hepatitis C Virus Vaccine Encoding NS3 Linked to the MHC Class II Chaperone Protein Invariant Chain

4. Fusion of a viral antigen to invariant chain leads to augmented T-cell immunity and improved protection in gene-gun DNA-vaccinated mice

5. Immunization with a Lentiviral Vector Stimulates both CD4 and CD8 T Cell Responses to an Ovalbumin Transgene

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Preferential Expansion of HPV16 E1-Specific T Cells from Healthy Donors’ PBMCs after Ex Vivo Immunization with an E1E2E6E7 Fusion Antigen;Cancers;2023-12-15

2. HBV001: Phase I study evaluating the safety and immunogenicity of the therapeutic vaccine ChAdOx1-HBV;JHEP Reports;2023-11

3. A hub gene signature as a therapeutic target and biomarker for sepsis and geriatric sepsis-induced ARDS concomitant with COVID-19 infection;Frontiers in Immunology;2023-09-26

4. Tolerogenic IL-10-engineered dendritic cell-based therapy to restore antigen-specific tolerance in T cell mediated diseases;Journal of Autoimmunity;2023-07

5. DC-targeting lentivectors for cancer immunotherapy;Immunotherapy Advances;2023-01-01